Tallan Client Abiomed Featured on CNBC for Innovation in Medical Technology
We are incredibly impressed by the innovation our client, Abiomed continues to deliver and are humbled to be a part of this life-saving solution.
The Food and Drug Administration has approved the emergency use of Abiomed’s Impella heart pump to help treat Covid-19 patients suffering from heart and lung failure, the company announced Tuesday.
In 1 in 10 patients, the virus results in extreme inflammation of the heart, in addition to a build-up of fluid in the lungs. For 42-year-old Devan Smith, who had no history of heart disease, the combination proved nearly fatal in May. (CNBC.com)
To read full article, click here.